Home›Trial›NCT07108894
🔬NCT07108894Phase 1RECRUITING

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

Study Summary

This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo

Conditions
Healthy Volunteers
Interventions / Drugs
ABCL575Placebo (Normal Saline 0.9%)
View on ClinicalTrials.gov ↗
Sponsor
ABCL
AbCellera Biologics
Antibody Discovery
C55/100
Study Details
Enrollment40 participants
Primary Completion—
Lead SponsorAbCellera Biologics Inc.
Data Retrieved2026-04-11 02:51:52.778521+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.